| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Small Molecules | Oncology | ||
IND Submission example | IND | — | Subscribe to access the data. | Small Molecules | Oncology | ||
IND Submission example | IND | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Monte Rosa Therapeutics, Inc.$22.98
-0.43 (-1.84%)
D 38Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.59 B
EPS
-1.63
P/E Ratio
-
Value Trade
15.54 M
SEC Financials
Q1 2026Dilution Risk
Revenue
4.21 M
R&D Expenses
44.07 M
Operating CF
-37.37 M
Total Assets
736.43 M
Total Liabilities
214.51 M
Equity
521.92 M
D/E Ratio
12,345
1.9 %
Week
-11.81 %
1 Month
-0.58 %
3 Month
39.85 %
6 Month
-14.5 %
5 Year
-14.5 %
All Time
Cash Data
Cash Position
666.22 M
Monthly Burn
12.46 M
Runway
51.3 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
482.37 K
52 Week Range
3.90 - 25.77
% held by Insiders
29.27 %
% held by Institutions
85.67 %
Enterprise Value
961.90 M
Total Shares
65.15 M
Short %
31.19 %
Float Shares
49.32 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Monte Rosa Therapeutics, Inc.
177Total events
4Upcoming
31Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Trial InitiationMRT-2359Trial
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-07-01 | MRT-2359 | phase 2 data readout | Phase 2 | — | – | – | – |
2026-07-01 | MRT-2359 | phase 2 data readout | Phase 2 | — | – | – | – |
2026-07-01 | MRT-2359 | phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D38
Pipeline Score $112M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 53%
Micro Cap (rank 430 of 912)
Percentile RankMonte Rosa Therapeutics, Inc. faces pipeline headwinds (38/100), with $281M risk-adjusted pipeline value, led by MRT-2359 in NSCLC (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRT-2359 Small molecule | NSCLC | Phase 1 | NCT05546268 | 5% | $141M | ACTIVE NOT_RECRUITING | 174 | FAST | D (32) | Nov 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MRT-8102 | elevated cardiovascular disease risk | Phase 1/2 | 2026-05-07 | CRP levels decreased by 85%; 94% of study participants achieved CRP levels below 2 mg/L Read More | Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with el Read More | |
MRT-8102 | elevated cardiovascular disease risk | Phase 1/2 | 2026-05-07 | CRP levels decreased by 85%; 94% of study participants achieved CRP levels below 2 mg/L Read More | Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with el Read More | |
MRT-8102 | elevated cardiovascular disease risk | Phase 1/2 | 2026-05-07 | CRP levels decreased by 85%; 94% of study participants achieved CRP levels below 2 mg/L Read More | Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with el Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GLUE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GLUE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GLUEMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Monte Rosa Therapeutics has granted inducement equity awards to four new non-executive employees as part of their employment agreement. The awards include stock options and restricted stock units, which will vest over time. This initiative is part of the company's strategy to enhance its workforce while adhering to Nasdaq Listing Rule 5635(c)(4). Monte Rosa is focused on developing novel molecular glue degrader medicines for serious diseases.
Read more →GLUE▲ +6.1%on this news
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Read more →GLUEMonte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with el
Monte Rosa Therapeutics reported financial results for Q1 2026, highlighting strong progress in its clinical programs. The interim data from the GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated substantial reductions in CRP levels among subjects at high cardiovascular risk. The company anticipates the initiation of multiple Phase 2 studies for MRT-8102 and MRT-2359 in various indications, including atherosclerotic risk and metastatic castration-resistant prostate cancer. Monte Rosa maintains a robust financial position with $671 million in cash and equivalents.
Read more →GLUE▲ +5.4%on this newsshared move
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2026
Monte Rosa Therapeutics announced the grant of inducement equity awards to four new non-executive employees as part of their employment package. The awards include non-qualified stock options and restricted stock units, which will vest over time. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting skilled professionals.
Read more →GLUEMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics presented preclinical data on MRT-55811, a cyclin E1-directed molecular glue degrader, at the AACR Annual Meeting 2026. The data showed that MRT-55811 induced significant tumor regressions in CCNE1-amplified cancer models, exhibiting high selectivity and reduced off-target effects compared to existing treatments. The company plans to submit an IND for MRT-55811 later this year.
Read more →GLUEMonte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics reported positive interim data for MRT-8102, showing significant reductions in CRP levels in patients at elevated cardiovascular risk. The company plans to initiate multiple Phase 2 studies for MRT-8102 and MRT-2359 in the coming years. Financially, Monte Rosa strengthened its position with a $345 million follow-on financing, supporting its development pipeline through 2029.
Read more →GLUEMonte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Read more →GLUEMonte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Monte Rosa Therapeutics presented updated clinical data for MRT-2359 at the ASCO GU Symposium, showing a 100% PSA response rate in mCRPC patients with AR mutations. The combination with enzalutamide demonstrated a 67% overall disease control rate. The treatment was well-tolerated, prompting plans for a Phase 2 study to further evaluate MRT-2359's efficacy.
Read more →GLUE▲ +8.7%on this news
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics has announced the pricing of an underwritten public offering, aiming to raise $300 million through the sale of 11,125,000 shares at $24.00 each. The offering includes pre-funded warrants for certain investors, representing further stock options. The proceeds are intended to support the company's development of novel molecular glue degrader (MGD)-based therapies. The offering is set to close on or around January 12, 2026, pending closing conditions.
Read more →GLUE▲ +45.4%on this news· ran to +58% by day 1shared move
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
Monte Rosa Therapeutics reported positive interim data from its Phase 1 study of MRT-8102, which showed significant reductions in C-reactive protein (CRP) levels in subjects at elevated cardiovascular disease risk. After four weeks of treatment, 94% of participants achieved CRP levels below the threshold associated with reduced CVD risk. The study also indicated a favorable safety profile and plans for further development in Phase 2 studies targeting atherosclerotic cardiovascular disease.
Read more →GLUE▲ +45.4%on this news· ran to +58% by day 1shared move
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Read more →GLUE▲ +11.2%on this news· ran to +69% by day 3shared move
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Read more →GLUE▲ +13.4%on this news
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
Monte Rosa Therapeutics reported promising interim results from its Phase 1/2 study of MRT-2359 combined with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring androgen receptor mutations. The treatment achieved a 100% PSA response rate and a 100% disease control rate among the evaluated patients. The company plans to initiate a Phase 2 study in 2026 to further confirm these findings.
Read more →GLUE▲ +13.4%on this newsshared move
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Monte Rosa Therapeutics will present updated results from its Phase 1/2 study of MRT-2359, targeting metastatic castration-resistant prostate cancer. The live conference call is scheduled for December 16, 2025, at 8:00 a.m. ET. The presentation will provide interim clinical results from the ongoing study, highlighting the company's advancements in molecular glue degrader medicines.
Read more →GLUE▲ +14.2%on this news
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Monte Rosa Therapeutics presented preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the AHA Scientific Sessions 2025. The data suggest that MRT-8102 could effectively modulate the NLRP3 inflammasome, potentially treating cardiovascular and cardiometabolic diseases. The company is currently enrolling participants for a Phase 1 study, with initial data expected in the first half of 2026.
Read more →GLUE▲ +5.7%on this news· ran to +16% by day 3shared move
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Monte Rosa Therapeutics reported strong financial results for Q3 2025, including a $120 million collaboration with Novartis for developing novel degraders. The company is advancing several clinical trials, including Phase 1 studies for MRT-8102 and MRT-6160, with initial data expected in H1 2026. Despite a net loss of $27.1 million, Monte Rosa's cash position remains robust, projected to support operations through 2028.
Read more →GLUE▲ +7.3%on this news· ran to +20% by day 3
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Monte Rosa Therapeutics presented promising preclinical data on MRT-6160, a molecular glue degrader targeting VAV1, at ACR Convergence 2025. The data indicate its potential effectiveness in treating autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The company plans to advance MRT-6160 into Phase 2 studies in collaboration with Novartis.
Read more →GLUE▲ +44.1%on this news
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
Monte Rosa Therapeutics has announced a collaboration with Novartis to develop novel molecular glue degraders for immune-mediated diseases. The agreement includes an upfront payment of $120 million and potential total payments up to $5.7 billion. This partnership aims to leverage Monte Rosa's AI/ML-enabled QuEEN™ platform to expedite the development of treatments targeting difficult-to-drug immune-mediated conditions.
Read more →GLUEMonte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic ap
Monte Rosa Therapeutics announced its financial results for Q2 2025, highlighting progress in its clinical programs. The company is advancing several Molecular Glue Degrader (MGD) therapies, including MRT-8102 for inflammatory diseases and MRT-2359 for prostate cancer. Financially, collaboration revenue has significantly increased, contributing to a robust cash position expected to fund operations until 2028. Additionally, initial data from ongoing studies are anticipated in the coming years, showcasing the company's growth trajectory and potential impact in the biotech landscape.
Read more →GLUEMonte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics has initiated a Phase 1 study for MRT-8102, a NEK7-directed molecular glue degrader aimed at treating inflammatory diseases. The study will assess safety, pharmacokinetics, and NEK7 protein degradation, with initial results expected in the first half of 2026. A specific cohort will evaluate potential early proof of concept for cardiovascular disease indications.
Read more →GLUEMonte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
Monte Rosa Therapeutics announced the publication of significant findings in Science, showcasing their AI-driven approach to molecular glue degrader (MGD) drug discovery. The research reveals a broad range of human proteins accessible for cereblon-based degradation, enhancing the potential for developing innovative therapies. This advancement supports Monte Rosa's mission to create transformative medicines for difficult-to-treat diseases.
Read more →GLUEMonte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Read more →GLUEMonte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
Read more →GLUE▲ +9.6%on this news
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad
Monte Rosa Therapeutics has announced substantial advancements and financial highlights for Q1 2025, featuring a strong focus on its VAV1-directed MRT-6160 program, which is set to advance to Phase 2 studies. The company reported a net income of $46.9 million, a significant improvement from the previous year's loss, and has outlined its pipeline developments, including MRT-2359 and MRT-8102. All programs are progressing as planned, with several IND submissions anticipated in 2025 and 2026. Collaboration with Novartis remains pivotal for advancing their therapeutic portfolio.
Read more →GLUEMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
Read more →GLUE▲ +5.4%on this news· ran to -15% by day 3
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs Results of the MRT-6160 Phase 1 SAD/MAD study demon
Monte Rosa Therapeutics has announced its fourth quarter 2024 financial results alongside significant updates on its clinical programs. The MRT-6160 Phase 1 study has shown promising results, including over 90% VAV1 degradation and a favorable safety profile. Additionally, MRT-2359 has revealed encouraging signals of clinical response in patients with castration-resistant prostate cancer, leading to a strategic focus on this patient cohort. The company maintains a strong cash position, allowing for sustained operations into 2028.
Read more →GLUEMonte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
Read more →GLUE▼ -6.1%on this news
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Read more →GLUEMonte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Read more →GLUEMonte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Read more →GLUEMonte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Addit
Monte Rosa Therapeutics has announced its anticipated milestones for 2025, highlighting progress in various clinical studies. The company expects initial clinical data from its Phase 1 trials, including MRT-6160 and MRT-2359, in the first quarter. Additionally, Monte Rosa has secured a robust cash position projected to fund operations until 2028, aided by a significant licensing agreement with Novartis. The company is also on track to file an IND application for MRT-8102 in the first half of 2025, further advancing its innovative pipeline of molecular glue degraders.
Read more →GLUEMonte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Read more →GLUE▼ -9.9%on this newsshared move
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Read more →GLUE▼ -9.9%on this newsshared move
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Read more →GLUEMonte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a f
Monte Rosa Therapeutics provided updates on its Phase 1/2 study of MRT-2359 for treating MYC-driven solid tumors. The interim results show a favorable safety profile with significant GSPT1 degradation achieved. The recommended Phase 2 dose has been set at 0.5 mg daily with a dosing schedule of 21 days on, 7 days off. Future updates, including additional clinical data, are expected in Q1 2025.
Read more →GLUEMonte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Read more →GLUE▼ -5.5%on this news· ran to -17% by day 3
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Read more →GLUEMonte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed mo
Monte Rosa Therapeutics reported its financial results for Q3 2024, highlighting a significant collaboration with Novartis for VAV1-directed molecular glue degraders. This partnership includes a $150 million upfront payment and potential milestones of up to $2.1 billion as they advance their clinical pipeline. Key studies for their candidates MRT-6160 and MRT-2359 are ongoing, with initial clinical data expected to be released by early 2025. Overall, Monte Rosa demonstrated a strengthened cash position, enabling continued development of its innovative therapies.
Read more →GLUE▲ +93.9%on this news
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders Agreement expected to accelerate MRT-6160 clinical development and broadl
Monte Rosa Therapeutics has entered a global license agreement with Novartis to develop VAV1-directed molecular glue degraders, including MRT-6160, which is currently in Phase 1 clinical studies. As part of the agreement, Monte Rosa will receive an up-front payment of $150 million, with potential total payments of up to $2.1 billion based on milestone achievements. Novartis will handle the subsequent Phase 2 and 3 trials and commercialization of MRT-6160, which shows promise for treating immune-mediated conditions based on preclinical data. The deal is expected to enhance Monte Rosa's operational capacity and development pipeline.
Read more →GLUE▼ -8.3%on this news· ran to +79% by day 3shared move
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
Read more →GLUEMonte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Read more →GLUE▲ +10.2%on this news· ran to +34% by day 3
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune disea
Monte Rosa Therapeutics announced its second quarter 2024 financial results, highlighting the IND clearance for MRT-6160, a significant achievement for the company. The firm is set to initiate a Phase 1 study for MRT-6160 and expects early clinical data by Q1 2025. Additionally, MRT-2359 is advancing in its ongoing Phase 1/2 study, showing promising safety profiles. The company also reported substantial revenues from its collaboration with Roche and maintained a strong cash position to support its operations through various anticipated clinical milestones.
Read more →GLUE▲ +6.9%on this news
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
Read more →GLUE▼ -8.4%on this news
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5
Monte Rosa Therapeutics has provided updates on its lead programs, MRT-2359 and MRT-6160. The Phase 1/2 study of MRT-2359 for MYC-driven solid tumors is progressing well, demonstrating a favorable safety profile at a 0.5 mg dose, leading to the initiation of a higher 0.75 mg dose cohort. MRT-6160's IND application has been submitted, with plans to begin Phase 1 studies for autoimmune diseases later this summer. Both programs are set to provide updated clinical data by H2 2024 and Q1 2025, respectively.
Read more →GLUEMonte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Read more →GLUEMonte Rosa Therapeutics Announces Leadership Team Promotions
Monte Rosa Therapeutics has announced promotions for three key members of its leadership team: Sharon Townson to Chief Scientific Officer, Phil Nickson to Chief Business and Legal Officer, and Jennifer Champoux to Chief Operating Officer. These promotions reflect their substantial contributions to advancing the company's drug development initiatives and enhancing its operational capabilities. The leadership team aims to leverage their expertise and the company's AI/ML-driven discovery engine to continue developing novel molecular glue degrader medications targeting cancers and immune-related conditions.
Read more →GLUEMonte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
Read more →GLUE▼ -13.2%on this news
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Read more →GLUEMonte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
Monte Rosa Therapeutics has announced the pricing of a public offering, raising $100 million through the sale of 10,638,476 shares at $4.70 each. The offering is expected to close on or around May 20, 2024, contingent on standard closing conditions being met. Funds raised will be utilized for advancing the company's research on novel molecular glue degrader-based therapies. The financing was led by Dimension and included participation from other investors, highlighting continued interest in the biotech sector.
Read more →GLUEMonte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 c
Monte Rosa Therapeutics reported its first quarter 2024 financial results alongside significant clinical updates. The company is advancing MRT-2359, a molecular glue degrader, in a Phase 1/2 trial for MYC-driven solid tumors, with key milestones projected for 2024. Other candidates, MRT-6160 and MRT-8102, are also on track for IND submissions and clinical trials in the coming years. Furthermore, Monte Rosa announced a new discovery program targeting CCNE1, enhancing its pipeline for oncology treatment. The company maintains a robust cash position expected to sustain operations into mid-2026.
Read more →GLUE▼ -5.7%on this news
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer Dr. Wallace will depart his role as CSO effective
Monte Rosa Therapeutics announced the departure of Owen Wallace, Ph.D., from his role as Chief Scientific Officer, effective May 17, 2024. He will transition to a CEO role at a UK-based biotechnology firm but will remain involved with Monte Rosa as a scientific advisor on its Scientific Advisory Board. The company expressed gratitude for his contributions and emphasized the continued leadership of its drug discovery team as they pursue advancements in their MGD programs. Monte Rosa aims to leverage its innovative QuEEN drug discovery engine to develop therapies for serious diseases.
Read more →GLUE▼ -8.4%on this news
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongo
Monte Rosa Therapeutics reported its Q4 and full year 2023 financial results, highlighting significant advancements in its clinical pipeline. The company is progressing with MRT-2359 for MYC-driven solid tumors, with promising initial Phase 1/2 results showing tumor size reductions. Additionally, MRT-6160 is expected to submit an IND application by Q2 2024, and the company has entered a strategic collaboration with Roche, enhancing its research capabilities. Overall, Monte Rosa maintains a strong cash position, expected to sustain operations until mid-2026.
Read more →GLUEMonte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
Read more →GLUE▼ -8.5%on this news· ran to -29% by day 3
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Rece
Monte Rosa Therapeutics has provided an update on its clinical and corporate milestones for 2024. The company is on track with its Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors and has received FDA Fast Track Designation for MRT-2359. Preparations are underway to announce the recommended Phase 2 dose in Q2 2024. Additionally, the company is set to present at the J.P. Morgan Healthcare Conference on January 10, 2024, outlining its strategic priorities and anticipated advancements in its pipeline, including MRT-6160.
Read more →GLUE▲ +14.4%on this news· ran to +40% by day 1shared move
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Read more →GLUEMonte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read more →GLUE▼ -8.3%on this news
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
Read more →GLUE▼ -10.6%on this news
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positiv
Monte Rosa Therapeutics reported positive interim data from its Phase 1/2 trial of MRT-2359, showing tumor reductions in patients with biomarker-positive cancers. The company announced a strategic collaboration with Roche, including a $50 million upfront payment aimed at accelerating development of molecular glue degraders. Monte Rosa is also advancing other pipeline projects, with expectations for continued funding into the first half of 2026. However, the company faced a net loss of $34.9 million and has shifted focus away from its sickle cell disease program.
Read more →GLUE▲ +6.9%on this newsshared move
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
Read more →GLUEMonte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
Monte Rosa Therapeutics announced a successful $25 million registered direct offering, aimed at supporting its clinical pipeline, including MRT-2359 and MRT-6160. The company is issuing 10,000,400 pre-funded warrants priced at $2.4999 each, a figure aligned with their stock's previous closing price. The closing of this offering is expected by October 30, 2023, pending customary conditions. Proceeds will be directed toward clinical advancements in oncology and other serious diseases treatments using their innovative molecular glue degrader technology.
Read more →GLUE▼ -19.8%on this news· ran to -45% by day 3
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
Read more →GLUE▼ -19.8%on this news· ran to -45% by day 3
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases Collaboration combines Monte Rosa Therapeutics' highly differenti
Monte Rosa Therapeutics has entered a strategic collaboration with Roche to develop novel molecular glue degraders targeting cancer and neurological diseases. The agreement entails an upfront payment of $50 million and potential future payments exceeding $2 billion, along with royalties. Monte Rosa's QuEEN discovery engine will drive the discovery of highly selective molecular glue degraders, while Roche will lead further development. The alliance aims to enhance treatment options for previously difficult-to-drug targets in oncology and neuroscience.
Read more →GLUEMonte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update ● On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the
Monte Rosa Therapeutics reported its financial results for Q2 2023, highlighting significant advancements in its clinical programs. The company is on track to present initial data from its Phase 1/2 clinical trial of MRT-2359 targeting MYC-driven solid tumors later this year. Additionally, it received FDA Orphan Drug Designation for MRT-2359 for small cell lung cancer and announced the development of MRT-6160 for treating autoimmune diseases. Despite a net loss of $35.2 million for the quarter, Monte Rosa's strong cash reserves are expected to support operations through 2025.
Read more →GLUEMonte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
Read more →GLUE▲ +5.2%on this news· ran to +22% by day 3
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
Read more →GLUEMonte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
Read more →GLUEMonte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update • On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the s
Monte Rosa Therapeutics reported its first quarter 2023 results, noting significant progress in its Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors. The company remains on track to present initial trial data in the second half of 2023 and announced a cash runway extending into 2025. Additionally, preclinical data from MRT-2359 shows promising therapeutic potential, and a new board member has been appointed to strengthen strategic oversight. However, the company faced an increase in net loss and expenses over the previous year.
Read more →GLUEMonte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
Read more →GLUEMonte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
Read more →GLUE▲ +7.4%on this news
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update • Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing &
Monte Rosa Therapeutics reported its financial results for Q4 and the full year 2022, highlighting key developments including the ongoing Phase 1/2 trial of MRT-2359 for MYC-driven solid tumors. The drug has received Fast Track designation from the FDA, boosting its development timeline for metastatic NSCLC. The company reported a year-end cash balance of approximately $268 million but also recorded significant losses, emphasizing the financial challenges ahead. Looking forward, Monte Rosa anticipates disclosing initial clinical data in the latter half of 2023 and nominating multiple development candidates throughout the year.
Read more →GLUE▲ +15.1%on this news
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
Read more →GLUE▼ -14.3%on this news
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
Read more →GLUE▼ -14.3%on this news
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” includi
Monte Rosa Therapeutics is advancing its molecular glue degraders (MGDs) to address previously undruggable proteins in drug development. The company announced five programs targeting unmet medical needs, with a specific focus on oncology and autoimmune diseases. Their ongoing clinical trial for MRT-2359 demonstrates their commitment to innovation in the field. Additionally, with a robust financial position, Monte Rosa has significant resources to support its pipeline and research efforts moving forward.
Read more →GLUEMonte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Read more →GLUE▲ +5.3%on this news· ran to +24% by day 3
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates – Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for T
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors Progressed VAV1 Molecular Glue Degrad
Read more →GLUEMonte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
Read more →GLUE▲ +6%on this newsshared move
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
Read more →GLUEMRT-2359 KOL Webinar hosted by Cowen
Speakers Jordi Rodon Ahnert, M.D., Ph.D., Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center Davide Ruggero, Ph.D., Professor, Department of Urology and Cellular & Molecular Pharmacology at UCSF; Helen Diller Family Endowe
Read more →GLUEMonte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
Read more →GLUEMonte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader
Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader
Read more →GLUE▲ +5.2%on this news
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates – Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Trea
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors Cash Runway into Late 2024 with $2
Read more →GLUE▼ -16%on this news
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates – Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSP
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Trac
Read more →GLUEMonte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022
Read more →GLUE▲ +16.3%on this news· ran to +35% by day 3
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates – Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 Progressed NEK7 and CDK2 Molecular Glue Degrader Programs into
Read more →GLUE▼ -9.9%on this news
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
Read more →GLUEThese materials include express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements includ
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2022 Exhibit 99.1 These materials include express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Litigation
Read more →GLUEMonte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Read more →GLUEMonte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
Read more →GLUEMonte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
Read more →GLUEMonte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular G
Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 Preclinical Dat
Read more →GLUE▲ +5.4%on this news
Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit
Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit
Read more →GLUEMonte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
Read more →GLUEMonte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
Read more →GLUEMonte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes
Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes
Read more →GLUE▼ -13.5%on this newsshared move
Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
Read more →GLUEMonte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress Completed upsized $255.6 million IPO; cash runway extended into late 2024 Continued advancement of QuEEN
Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress Completed upsized $255.6 million IPO; cash runway extended into late 2024 Continued advancement of QuEENTM protein degradation platform and pipeline of molecula
Read more →GLUEMonte Rosa Therapeutics Announces Pricing of Initial Public Offering
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
Read more →GLUEMonte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical Officer
Monte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical Officer
Read more →GLUEMonte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
Read more →GLUEMonte Rosa Therapeutics Strengthens Leadership with Key Executive and Board Appointments
Monte Rosa Therapeutics Strengthens Leadership with Key Executive and Board Appointments
Read more →GLUEMonte Rosa Therapeutics Expands Senior Management Team
Monte Rosa Therapeutics Expands Senior Management Team
Read more →GLUEMonte Rosa Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Read more →GLUEMonte Rosa Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
Monte Rosa Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
Read more →GLUEMonte Rosa Therapeutics Announces Formation of Scientific Advisory Board
Monte Rosa Therapeutics Announces Formation of Scientific Advisory Board
Read more →GLUEMonte Rosa Therapeutics Strengthens Executive Leadership Team with New Appointments
Monte Rosa Therapeutics Strengthens Executive Leadership Team with New Appointments
Read more →GLUEMonte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform
Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform
Read more →GLUEMonte Rosa Therapeutics Discloses $32.5 Million Financing
Monte Rosa Therapeutics Discloses $32.5 Million Financing
Read more →GLUEVersant Ventures Strengthens Global Team and Discovery Engine Infrastructure
Versant Ventures Strengthens Global Team and Discovery Engine Infrastructure
Read more →Competitive Position
How GLUE ranks across every disease it competes inCompetitive Position is a premium feature
See how GLUE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial